Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD

Neurology

Volumn 80, Issue 7, 2013, Pages 627-633

  Velseboer, Daan C ^a   Broeders, Mark ^a   Post, Bart ^b   Van Geloven, Nan ^a   Speelman, Johannes D ^a   Schmand, Ben ^a   De Haan, Rob J ^a   De Bie, Rob M A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PROPRANOLOL; ANTIPARASITIC AGENT;

ADULT; AGED; ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; DISABILITY; DISEASE COURSE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; SEX DIFFERENCE; UNIFIED PARKINSON DISEASE RATING SCALE; DISABLED PERSON; MIDDLE AGED; MOTOR ACTIVITY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARASITIC AGENTS; COHORT STUDIES; DISABILITY EVALUATION; DISABLED PERSONS; DISEASE PROGRESSION; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; PROGNOSIS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84875822485     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318281cc99     Document Type: Article

References (31)

1. Foltynie T, Brayne C, Barker RA. The heterogeneity of idiopathic Parkinson's disease. J Neurol 2002;249:138-145.
2. Post B, Merkus MP, de Haan RJ, Speelman JD; CARPA Study Group. Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov Disord 2007;22: 1839-1851.
3. Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 2002;59:1724-1728.
4. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:968-975.
5. Post B, Speelman JD, de Haan RJ; CARPA-Study Group. Clinical heterogeneity in newly diagnosed Parkinson's disease. J Neurol 2008;255:716-722.
6. Post B, Muslimovic D, van Geloven N, et al. Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease. Mov Disord 2011;26:449-456.
7. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
8. Esselink RA, de Bie RM, de Haan RJ, et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. Neurology 2004;62:201-207.
9. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
10. Fahn S, Elton RL; Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, editors. Recent Developments in Parkinson's Disease. Florham Park: Macmillan Healthcare Information; 1987:153-163.
11. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson MC, editors. Third Symposium on Parkinson's Disease. Edinburgh: E & S Livingstone; 1969:152-157.
12. Weisscher N, Post B, de Haan RJ, Glas CA, Speelman JD, Vermeulen M. The AMC Linear Disability Score in patients with newly diagnosed Parkinson disease. Neurology 2007; 69:2155-2161.
13. de Boer AG, Wijker W, Speelman JD, de Haes JC. Quality of life in patients with Parkinson's disease: development of a questionnaire. J Neurol Neurosurg Psychiatry 1996;61:70-74.
14. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968;16:622-626.
15. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale: an updated literature review. J Psychosom Res 2002;52:69-77.
16. Marinus J, Leentjens AF, Visser M, Stiggelbout AM, van Hilten JJ. Evaluation of the hospital anxiety and depression scale in patients with Parkinson's disease. Clin Neuro-pharmacol 2002;25:318-324.
17. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005;65:1239-1245.
18. Levy G, Tang MX, Cote LJ, et al. Motor impairment in PD: relationship to incident dementia and age. Neurology 2000;55:539-544.
19. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.
20. Muslimovic D, Post B, Speelman JD, De Haan RJ, Schmand B. Cognitive decline in Parkinson's disease: a prospective longitudinal study. J Int Neuropsychol Soc 2009;15:426-437.
21. Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ. Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. Brain 2007; 130:2123-2128.
22. Kempster PA, O'Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010;133:1755-1762.
23. Evans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry 2011;82:1112-1118.
24. Greffard S, Verny M, Bonnet AM, et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia Nigra. Arch Neurol 2006;63:584-588.
25. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008;115:409-415.
26. Alves G, Müller B, Herlofson K, et al. Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2009;80: 851-857.
27. Haaxma CA, Bloem BR, Borm GF, et al. Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:819-824.
28. Shulman LM. Gender differences in Parkinson's disease. Gend Med 2007;4:8-18.
29. Dluzen DE, McDermott JL. Neuroprotective role of estrogen upon methamphetamine and related neurotoxins within the nigrostriatal dopaminergic system. Ann NY Acad Sci 2000;914:112-126.
30. Marras C, Lang A, Krahn M, Tomlinson G, Naglie G; Parkinson Study Group. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov Disord 2004;19:22-28.
31. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004;127:550-560.